Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05954312 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Vividion Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 290
- Enrollment target
- 20
- Study locations
NCT05954312 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Vividion Therapeutics. The registered enrollment target is 290 participants, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (47% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT05954312, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Vividion Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 290 participants
- Enrollment target
- 20
- Study locations
Study Summary
A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Docetaxel
- DRUG Paclitaxel
- DRUG VVD-130037
Study Locations (20)
Other
- National Cancer Center - Goyang
- Gachon University Gil Medical Center - Incheon
- Seoul National University; Bundang Hospital - Seongnam
- Asan Medical Center - Seoul
- Samsung Medical Center - Seoul
- Seoul National University Hospital - Seoul
- Severance Hospital; Yonsei University Health System - Seoul
- The Catholic University of Korea, St. Vincent's Hospital - Suwon
- Hospital Vall d'Hebron - Barcelona
- START Barcelona Hospital HM Nou Delfos - Barcelona
- Hospital Universitario 12 de Octubre - Madrid
- Hospital Universitario Ramon y Cajal - Madrid
Florida
- Mayo Clinic Jacksonville - Jacksonville
- Florida Cancer Specialists - Sarasota
- Moffitt Cancer Center - Tampa
Texas
- MDACC - Houston
- NEXT Dallas - Irving
Minnesota
- Mayo Clinic Rochester - Rochester
Tennessee
- Sarah Cannon Research Institute - Nashville
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2023-07-28 |
| Est. Completion | 2031-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05954312
The ClinicalTrials.gov registry entry for NCT05954312 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (47% higher). The listed sponsor is Vividion Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT05954312 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT05954312 about?
NCT05954312 is a clinical study titled "A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors". A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.
What is the current status of trial NCT05954312?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 290 participants. The study started on 2023-07-28. Estimated completion is 2031-02-28.
What conditions does trial NCT05954312 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT05954312?
The interventions under investigation include: Pembrolizumab (DRUG), Docetaxel (DRUG), Paclitaxel (DRUG), VVD-130037 (DRUG).
Who is sponsoring clinical trial NCT05954312?
This trial is sponsored by Vividion Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05954312 being conducted?
This trial has 20 study locations across Florida, Minnesota, Tennessee, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.